243.09
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RMD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$244.70
Offen:
$245.74
24-Stunden-Volumen:
737.77K
Relative Volume:
0.72
Marktkapitalisierung:
$35.70B
Einnahmen:
$5.02B
Nettoeinkommen (Verlust:
$1.31B
KGV:
27.28
EPS:
8.91
Netto-Cashflow:
$1.56B
1W Leistung:
+2.79%
1M Leistung:
+18.85%
6M Leistung:
-3.68%
1J Leistung:
+14.19%
Resmed Inc Stock (RMD) Company Profile
Firmenname
Resmed Inc
Sektor
Telefon
(858) 746-2400
Adresse
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Vergleichen Sie RMD mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
RMD
Resmed Inc
|
243.09 | 35.70B | 5.02B | 1.31B | 1.56B | 8.91 |
![]()
ISRG
Intuitive Surgical Inc
|
538.16 | 185.37B | 8.71B | 2.48B | 1.75B | 6.82 |
![]()
BDX
Becton Dickinson Co
|
167.95 | 48.59B | 20.87B | 1.50B | 2.59B | 5.24 |
![]()
ALC
Alcon Inc
|
95.88 | 47.57B | 9.91B | 1.02B | 665.00M | 2.05 |
![]()
COO
The Cooper Companies, Inc.
|
82.92 | 16.51B | 3.90B | 392.30M | 288.10M | 1.95 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-19 | Eingeleitet | Morgan Stanley | Overweight |
2025-01-16 | Eingeleitet | Goldman | Buy |
2025-01-10 | Eingeleitet | Piper Sandler | Neutral |
2024-12-13 | Eingeleitet | Stifel | Hold |
2024-09-24 | Eingeleitet | Robert W. Baird | Outperform |
2024-09-18 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
2024-09-04 | Herabstufung | Needham | Buy → Hold |
2024-06-25 | Herabstufung | Oppenheimer | Outperform → Perform |
2024-06-24 | Herabstufung | Citigroup | Buy → Neutral |
2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
2023-10-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2023-10-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2023-10-09 | Hochstufung | JP Morgan | Neutral → Overweight |
2023-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
2023-09-06 | Hochstufung | Needham | Hold → Buy |
2023-09-05 | Herabstufung | UBS | Buy → Neutral |
2023-08-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2023-05-23 | Eingeleitet | UBS | Buy |
2023-04-14 | Eingeleitet | Mizuho | Buy |
2023-01-17 | Hochstufung | JP Morgan | Neutral → Overweight |
2022-10-28 | Herabstufung | Citigroup | Buy → Neutral |
2022-10-20 | Hochstufung | BofA Securities | Neutral → Buy |
2022-10-12 | Eingeleitet | Jefferies | Hold |
2022-09-08 | Hochstufung | Citigroup | Neutral → Buy |
2022-08-15 | Herabstufung | CLSA | Buy → Outperform |
2022-08-12 | Herabstufung | Citigroup | Buy → Neutral |
2022-08-12 | Herabstufung | JP Morgan | Overweight → Neutral |
2022-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2022-06-06 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
2022-01-31 | Hochstufung | Goldman | Neutral → Buy |
2022-01-28 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
2022-01-24 | Hochstufung | BofA Securities | Underperform → Neutral |
2022-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
2022-01-13 | Hochstufung | CLSA | Outperform → Buy |
2022-01-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
2021-12-21 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
2021-12-06 | Hochstufung | Macquarie | Neutral → Outperform |
2021-10-22 | Hochstufung | CLSA | Underperform → Outperform |
2021-08-02 | Herabstufung | CLSA | Outperform → Sell |
2021-08-02 | Herabstufung | Needham | Buy → Hold |
2021-07-28 | Hochstufung | Jefferies | Underperform → Hold |
2021-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
2021-07-14 | Eingeleitet | RBC Capital Mkts | Underperform |
2021-06-28 | Herabstufung | Citigroup | Buy → Neutral |
2021-06-22 | Hochstufung | Macquarie | Neutral → Outperform |
2021-06-22 | Eingeleitet | Robert W. Baird | Neutral |
2021-06-21 | Bestätigt | Needham | Buy |
2021-06-16 | Herabstufung | BofA Securities | Neutral → Underperform |
2021-06-09 | Hochstufung | CLSA | Sell → Outperform |
2021-05-21 | Hochstufung | JP Morgan | Neutral → Overweight |
2021-05-11 | Hochstufung | Citigroup | Neutral → Buy |
2021-04-30 | Herabstufung | Citigroup | Buy → Neutral |
2021-03-16 | Hochstufung | Needham | Hold → Buy |
2020-11-02 | Hochstufung | UBS | Neutral → Buy |
2020-10-30 | Hochstufung | JP Morgan | Underweight → Neutral |
2020-10-27 | Hochstufung | BofA Securities | Underperform → Neutral |
2020-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2020-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2020-05-01 | Herabstufung | JP Morgan | Neutral → Underweight |
2020-05-01 | Hochstufung | Oppenheimer | Perform → Outperform |
2020-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2020-02-03 | Eingeleitet | CLSA | Underperform |
2020-01-31 | Herabstufung | UBS | Buy → Neutral |
2020-01-10 | Eingeleitet | Oppenheimer | Perform |
2019-11-22 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
2019-07-29 | Hochstufung | UBS | Neutral → Buy |
2019-07-16 | Herabstufung | UBS | Buy → Neutral |
2019-05-06 | Hochstufung | UBS | Neutral → Buy |
2019-04-18 | Hochstufung | JP Morgan | Underweight → Neutral |
2019-01-25 | Herabstufung | Goldman | Buy → Neutral |
2019-01-25 | Herabstufung | JP Morgan | Neutral → Underweight |
2018-10-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
2018-07-02 | Eingeleitet | Goldman | Buy |
Alle ansehen
Resmed Inc Aktie (RMD) Neueste Nachrichten
Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RMD) - GuruFocus
Resmed prevails over Cleveland Medical in CPAP patent review - BioWorld MedTech
Is ResMed Inc.'s (NYSE:RMD) Latest Stock Performance A Reflection Of Its Financial Health? - simplywall.st
Ex-Dividend Reminder: Seaboard, KB Home and ResMed - Nasdaq
ResMed Inc Reports Changes in CDIs and Securities for April 2025 - TipRanks
Jim Cramer on Viemed Healthcare (VMD): “Interesting, But I’m a ResMed Guy” - Yahoo Finance
ResMed Wins Invalidation of Sleep Apnea Tech Patent After Remand - Bloomberg Law News
Is It Smart To Buy ResMed Inc. (NYSE:RMD) Before It Goes Ex-Dividend? - Yahoo Finance
ResMed Corporation: GLP-1 Demand Generation Strategy to Expand Customer Base & Strengthen Their Position! - Smartkarma
Intuitive wins new FDA nod for single port robot; Resmed buys diagnostic facility - MedTech Dive
This ResMed Insider Reduced Their Stake By 72% - Yahoo Finance
Resmed acquires independent diagnostic testing facility VirtuOx - Yahoo Finance
Resmed Acquires Virtual Care Company VirtuOx - Medical Product Outsourcing
ResMed (RMD) Expands with VirtuOx Acquisition - GuruFocus
Resmed Acquires VirtuOx - Nasdaq
ResMed Buys VirtuOx for Undisclosed sum - marketscreener.com
Resmed (RMD) Expands Reach with Acquisition of VirtuOx | RMD Sto - GuruFocus
Resmed acquires virtual diagnostics company VirtuOx - MassDevice
Resmed (RMD) Expands Reach with Acquisition of VirtuOx | RMD Stock News - GuruFocus
Why ResMed (RMD) is a Top Growth Stock for the Long-Term - Yahoo Finance
ResMed announces it has acquired VirtuOx - TipRanks
Resmed Inc (RMD): Jim Cramer Says “Remarkable Stock” — Did GLP-1 Drugs Just Hand It a Lifeline? - Insider Monkey
This ASX medical device company has a Trump tariff exemption - MSN
Resmed Hires Chief Investor Relations Officer - HME Business
Press Release Distribution & PR Platform - ACCESS Newswire
ResMed Inc. Files Quarterly Report, Reinforces Market Position - MSN
ASX healthcare leader continues to prove the doubters wrong - Morningstar
What does Macquarie think ResMed shares are worth? - MSN
ResMed brushes off tariff threat - Intelligent Investor
ResMed Q3 Earnings and Revenues Beat, Stock Up in After-Market - MSN
ResMed Q1 2025: Strong Sales Growth and Strategic InitiativesNews and Statistics - IndexBox
ResMed Inc. (NYSE:RMD) Q3 2025 Earnings Call Transcript - Insider Monkey
ResMed Inc’s Earnings Call Highlights Growth and Innovation - TipRanks
ResMed Inc (RMD)'s Winning Formula: Financial Metrics and Compet - GuruFocus
ResMed (RMD) is a Top-Ranked Momentum Stock: Should You Buy? - Yahoo Finance
Decoding ResMed Inc (RMD): A Strategic SWOT Insight - GuruFocus
ResMed Inc. stock rises Thursday, outperforms market - MSN
ResMed Boasts Double-Digit EPS Growth, Tariff Exemption: Analysts Boost Price ForecastResMed (NYSE:RMD) - Benzinga
ResMed (NYSE:RMD) Reports Strong Q3 Earnings Growth and Declares US$0.53 Dividend - Yahoo Finance
ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates - MSN
ResMed Inc (RMD) Shares Up 11.28% on Apr 24 - GuruFocus
ResMed price target raised to $255 from $247 at RBC Capital - TipRanks
Jefferies Adjusts Price Target on ResMed to $245 From $270, Maintains Hold Rating - marketscreener.com
Morgan Stanley Adjusts Price Target on ResMed to $286 From $280, Maintains Overweight Rating - marketscreener.com
ResMed stock holds as Oppenheimer maintains Perform rating By Investing.com - Investing.com Canada
Texas Instruments Posts Better-Than-Expected Results, Joins Community Health Systems, Hasbro, ServiceNow, ResMed And Other Big Stocks Moving Higher On ThursdayArdagh Metal Packaging (NYSE:AMBP), Allegion (NYSE:ALLE) - Benzinga
Stifel maintains ResMed stock hold rating and $240 target - Investing.com
Stifel maintains ResMed stock hold rating and $240 target By Investing.com - Investing.com UK
ResMed stock price target raised to $255 at RBC Capital - Investing.com
Piper Sandler cuts ResMed stock price target to $248 - Investing.com
Piper Sandler cuts ResMed stock price target to $248 By Investing.com - Investing.com UK
Finanzdaten der Resmed Inc-Aktie (RMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):